Featuring a slide presentation and related discussion from Dr Tiffany A Traina, including the following topics:

Extended follow-up with pembrolizumab/chemotherapy for patients with previously untreated PD-L1-positive metastatic triple-negative breast cancer (mTNBC) (0:00)
ASCENT trial: Survival advantage with sacituzumab govitecan versus physician's choice of chemotherapy for patients with relapsed/refractory TNBC (2:49)
Treatment-associated side effects with sacituzumab govitecan (5:32)
Activity of sacituzumab govitecan irrespective of TROP2 expression level and in patients with brain metastases (6:48)
Ongoing Phase III studies evaluating sacituzumab govitecan in earlier lines of treatment (eg, ASCENT-03, ASCENT-04) (8:51)
Efficacy and tolerability of trastuzumab deruxtecan in patients with HER2-low and HER2-ultralow metastatic breast cancer (10:26)
Activity and ongoing investigations of other novel agents and strategies for mTNBC (20:05)

When social media and real life collide: how to avoid being awkward in person